cardiovascular funding
30 open opportunities tagged cardiovascular, across federal agencies and private foundations. Sorted by deadline.
SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)
S. technology development and commercialization.
7 review criteria on fileAnimal and Biological Material Resource Centers (P40 Clinical Trial Not Allowed)
Objective ORIP uses the P40 mechanism to support Animal and Biological Material Resource Centers in a variety of areas of biomedical science.
9 review criteria on fileNHLBI Program Project Applications (P01 Clinical Trials Optional)
The National Heart, Lung, and Blood Institute (NHLBI) Program Project Grant (P01) supports research related to fundamental processes and diseases of the heart, blood and lymphatic vessels, lungs, and blood, including transfusion medicine, blood resources, and sleep disorders other programs including implementation science, health…
6 review criteria on fileResource-Related Research Projects for Development of Models and Related Materials for Studying Human Health and Diseases (R24 Clinical Trials Not Allowed)
Experimental research models are indispensable for studying the genetic basis and pathobiological mechanisms underlying human diseases, identifying drug targets, and developing effective preventive and therapeutic approaches.
7 review criteria on fileSingle Source: Post-Stroke Vascular Contributions to Cognitive Impairment and Dementia (VCID) in the United States (U19 - Clinical Trial Not Allowed)
his is a non-competitive funding opportunity intended to fund a single award.
9 review criteria on fileSingle Source Competition: Continuation of the Cardiovascular Repository for Type 1 Diabetes (CaRe-T1D) - Resource Center (U24 Clinical Trial Not Allowed)
This is a Notice of Funding Opportunity (NOFO) for a Single Source that will invite an application from an eligible organization to apply. Please see Section III.
7 review criteria on fileNHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
The objective of this Notice of Funding Opportunity (NOFO) is to support investigator-initiated, Phase 1 clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children. The proposed trial can be single or multi-site.
3 review criteria on fileNHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R61/R33 Clinical Trial Required)
The objective of this Notice of Funding Opportunity (NOFO) is to support investigator-initiated, Phase I clinical trials for diagnostic and therapeutic interventions for heart, lung, blood, and sleep (HLBS) disorders in adults and children.
3 review criteria on fileStimulating Hematology Investigation: New Endeavors (SHINE) (R01 Clinical Trial Not Allowed)
The Stimulating Hematology Investigation: New Endeavors (SHINE) program is intended to promote innovative, high-quality nonmalignant hematology research relevant to the missions of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institute of Aging (NIA), and the National Heart, Lung, and Blood…
3 review criteria on fileCausal Hypotheses on the Oral-Systemic Health Impacts of Human Behaviors among People with Chronic Conditions (U01 Clinical Trial Not Allowed)
6 years.25 billion fewer life years for the United States population.
3 review criteria on fileNHLBI TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (X01 - Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites applications to use NHLBI-funded TransOmics for Precision Medicine (TOPMed) program to access TOPMed capacity to generate a large volume of integrated genetic and multi-omics data to facilitate discovery of the molecular mechanisms of Heart, Lung, Blood, and Sleep (HLBS) disorders.
6 review criteria on fileContinuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)
Cardiovascular complications remain the leading cause of death among individuals with T1D despite the management of traditional risk factors such as high blood glucose, high blood pressure, and elevated cholesterol.
3 review criteria on fileINCLUDE Project: Transformative Research Awards for Down syndrome (R01 Clinical Trial Not Allowed)
The INCLUDE Transformative Research Award Program supports collaborative investigative teams or individual scientists who propose unusually innovative research projects, which, if successful, would have a major impact in understanding the biology of Down syndrome or related co-occurring conditions, or development of new treatments for…
3 review criteria on fileINCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)
Purpose The NIH INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE (INCLUDE) Project seeks to improve health and quality-of-life for individuals with Down syndrome.
3 review criteria on fileINCLUDE Project: Exploratory/Developmental Research Awards for Down syndrome (R21 Clinical Trial Not Allowed)
This Notice of Funding Opportunity (NOFO) invites researchers to submit applications for support of new exploratory and developmental research projects that address important gaps in Down syndrome research.
3 review criteria on fileNHLBI Clinical Trial Pilot Studies (R34 Clinical Trial Optional)
This Notice of Funding Opportunity Announcement (NOFO) intends to supports studies that are both necessary and sufficient to inform the planning of a Phase II-IV clinical trial within NHLBI's mission.
3 review criteria on fileNIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
This NOFO encourages applications for multi-site exploratory and confirmatory clinical trials focused on promising interventions; biomarker or outcome measure validation studies that are immediately preparatory to trials in stroke prevention, treatment, and recovery; and ancillary studies designed to add scientific aims to active studies…
3 review criteria on fileCatalyze: Product Definition for Small Molecules, Biologics, and Combination Products - Preliminary Product/Lead Series Identification and Combination Product Prototype (R33 - Clinical Trial Not Allowed)
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and…
4 review criteria on fileCatalyze: Product Definition Medical Device Prototype Optimization (R33 - Clinical Trial Not Allowed)
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and…
4 review criteria on fileCatalyze: Enabling Technologies and Transformative Platforms for HLBS Research (R33 - Clinical Trials Not Allowed)
This Notice of Funding Opportunity (NOFO) solicits grant applications to further develop enabling technologies and transformative platforms to catalyze next-generation predictive, diagnostic and therapeutic products to address heart, lung, blood, and sleep (HLBS)-related disorders and diseases.
3 review criteria on fileCatalyze Product Definition Medical Device prototype design/testing and disease target identification and assay development (R61/R33 - Clinical Trial Not Allowed)
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and…
4 review criteria on fileCatalyze: Product Definition for Small Molecules, Biologics and Combination Products - Target Identification and Validation, and Preliminary Product/Lead Series Identification (R61/R33 Clinical Trials Not Allowed)
The goal of the NHLBI Catalyze Program is to provide a comprehensive suite of support and services to facilitate the transition of basic science discoveries into viable diagnostic and therapeutic candidates that have been cleared for human testing, and to develop translational researchers fluent in product development and…
4 review criteria on fileDiabetes Research Centers (P30 Clinical Trial Optional)
Background According to the CDC, the prevalence of diabetes mellitus in the United States continues to rise over time.6% of the US Population) and about twice that prevalence in those over 65.
9 review criteria on fileNHLBI Emerging Investigator Award (EIA) (R35 Clinical Trial Optional)
The purpose of the NHLBI Emerging Investigator Award (EIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards (of which one must be an…
6 review criteria on fileNHLBI Outstanding Investigator Award (OIA) (R35 Clinical Trial Optional)
The purpose of the NHLBI Outstanding Investigator Award (OIA) is to promote scientific productivity and innovation by providing long-term support and increased flexibility to experienced Program Directors/Principal Investigators (PDs/PIs) who are currently PDs/PIs on at least two NHLBI R01-equivalent awards or an NHLBI R35 award in the…
6 review criteria on fileAmerican Heart Association — Research
Application Resources - Professional Heart Daily | American Heart Association Skip to main content There's still time to save on registration for Hypertension Scientific Sessions, October 7-11, 2026 Join us!
American Heart Association — Email our applications team >
2026 American Heart Association holidays: Jan. 1, Jan.
American Heart Association — 1-888-242-2453 (Inside U.S.)
) [email protected] About PHD Advertising Frequently Asked Questions (FAQs)
Open Philanthropy — Announcing the Strep A Vaccine Fund
Announcing the Strep A Vaccine Fund | Coefficient Giving Skip to Content Coefficient Giving Research / Announcements May 26, 2026 Announcing the Strep A Vaccine Fund By Alexander Berger and Katharine Collins Most people in wealthy countries know Strep A as the cause of strep throat, an uncomfortable but easily treated childhood illness.
Biophotonics
TheBiophotonicsprogram is part of the Engineering Biology and Health cluster, which also includes: 1) theBiosensingprogram; 2) theCellular and Biochemical Engineeringprogram; 3) theDisability and Rehabilitation Engineeringprogram; and 4) theEngineering of Biomedical Systemsprogram.
2 review criteria on file · agency frameworkSee which cardiovascular opportunities fit your work
An account is free and shows the full announcement, the review criteria reviewers score you against, and whether you are actually eligible — including the windows that close before the deadline does.
No card required.